Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Tolerability of CKD-386(5) vs. Co-administration of Components in Healthy Volunteers
NCT05698043Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Jul 2023
- Primary completion
- Sep 2023
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of telmisartan + rosuvastatin in hypertension (HTN) and dyslipidemia (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area Under the Concentration-time Curve from Time Zero to the Last Measurable Concentration at 72 hours and Maximum Plasma Concentration at 72 hours. Started Jul 2023; status: completed.
02
Drugs
telmisartan + rosuvastatin
03
Conditions
hypertension (HTN)dyslipidemia
Beyond the preview
Go deeper on NCT05698043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05698043.